ANTIBIOTIC SUSCEPTIBILITY PROFILE (JANUARY-DECEMBER 2011)
PERCENT SUSCEPTIBLE TO ACHIEVABLE SERUM LEVELS

Organism	ISOLATES [a]	AMIKACIN	AMOX/CLAV	AMPICILLIN	CEFAZOLIN	CEFOXITIN	CEFTAZIDIME	CEFTRIAXONE	CIPROFLOXACIN	CLINDAMYCIN	ERYTHROMYCIN	GENTAMICIN	IMIPENEM	LEVOFLOXACIN	NITROFURANTOIN [b]	OXACILLIN	PENICILLIN	PIP/TAZO	TETRACYCLINE	TOBRAMYCIN	TRIM/SULFA	VANCOMYCIN
RGHS Outpatient Sensitivities																						
Citrobacter freundii	185								97			95		88	92				81	98	85	
Enterobacter cloacae	203								99			99		98	22				90	99	90	
Enterococcus sp. [c]	1275			97					83[b]					84	96		97		28[b]			100[c]
Escherichia coli	9745		87	65		93		98	92			95		90	96				84	96	86	
Klebsiella pneumoniae	1407		93			93		99	99			99		99	29				90	99	95	
Proteus mirabilis	827		100	92		94		99	98			98		99	0				0	99	94	
Pseudomonas aerug	565						96		89			86		85						97		
MRSA/ORSA [d]	1461									74						0[d]			98		99	100
MSSA/OSSA [e]	2309				100					78	64				99	100			95		99	100
Staph sp coagulase neg	181				58					69	44				98	58			86		75	100

a=average number of isolates tested b=drug should be used for treatment of urinary tract infections only c=VRE (vancomycin resistant *Enterococcus*) prevalence was 5% for 2011

d=methicillin/oxacillin resistant *Staph. aureus* prevalence for 2011: 39% e=methicillin/oxacillin sensitive *Staph. aureus*

Streptococcus pneumoniae penicillin susceptibility was 95% for all isolates recovered during 2011 (n=219, 1% displayed high level resistance with MIC $\geq$2 µg/ml)

Prepared by:
Rochester General Hospital
Clinical Laboratories
Microbiology Department
585-922-4555

Roberto L. Vargas, M.D.
Director of Microbiology

Dawn Riedy, M.D.
Chief of Clinical Labs and Pathology